Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy?

R. S. Foster, J. P. Donohue

Research output: Contribution to journalArticle

32 Scopus citations

Abstract

The advances in the therapy of high-volume stage II and stage III testicular cancer have been largely due to the development and success of cisplatin-based chemotherapy. Though patients with low- to moderate-volume stage II disease historically were curable with radical retroperitoneal lymph node disssection, patients with higher volumes of metastatic disease were not curable with surgery alone. The advent of cisplatin-based chemotherapy in the 1970s has allowed many of these patients with higher-volume metastatic disease to be cured. Though chemotherapy clearly plays the major role in the therapy of these patients, surgery after chemotherapy has been complimentary in the overall chance for cure of these patients.

Original languageEnglish (US)
Pages (from-to)479-484
Number of pages6
JournalUrologic Clinics of North America
Volume25
Issue number3
DOIs
StatePublished - Jan 1 1998
Externally publishedYes

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Can retroperitoneal lymphadenectomy be omitted in some patients after chemotherapy?'. Together they form a unique fingerprint.

  • Cite this